These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11426031)

  • 1. WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis.
    Emery P; Reginster JY; Appelboom T; Breedveld FC; Edelmann E; Kekow J; Malaise M; Mola EM; Montecucco C; Sanda M; Sany J; Scott DL; Serni U; Seydoux G
    Rheumatology (Oxford); 2001 Jun; 40(6):699-702. PubMed ID: 11426031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour necrosis factor-alpha blockers in rheumatoid arthritis: review of the clinical experience.
    Richard-Miceli C; Dougados M
    BioDrugs; 2001; 15(4):251-9. PubMed ID: 11437690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].
    González-Gay MA; Agudo M
    Med Clin (Barc); 2010 May; 134(15):684-5. PubMed ID: 20176386
    [No Abstract]   [Full Text] [Related]  

  • 5. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of rheumatoid arthritis by TNF-blocking agents.
    Graninger W; Smolen J
    Int Arch Allergy Immunol; 2002 Jan; 127(1):10-4. PubMed ID: 11893849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical protocol for monitoring of targeted therapies in rheumatoid arthritis.
    Geborek P; Saxne T
    Rheumatology (Oxford); 2000 Oct; 39(10):1159-61. PubMed ID: 11035144
    [No Abstract]   [Full Text] [Related]  

  • 8. Etanercept and infliximab for rheumatoid arthritis.
    Drug Ther Bull; 2001 Jul; 39(7):49-52. PubMed ID: 11471515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
    Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA
    Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidance for practitioners on the assessment, administration and monitoring of biologic therapies for inflammatory arthritis.
    Oliver S
    Musculoskeletal Care; 2003 Sep; 1(2):135-40. PubMed ID: 20217674
    [No Abstract]   [Full Text] [Related]  

  • 11. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.
    Nuijten MJ; Engelfriet P; Duijn K; Bruijn G; Wierz D; Koopmanschap M
    Pharmacoeconomics; 2001; 19(10):1051-64. PubMed ID: 11735673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.
    Geborek P; Crnkic M; Petersson IF; Saxne T;
    Ann Rheum Dis; 2002 Sep; 61(9):793-8. PubMed ID: 12176803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
    Tijhuis GJ; van de Putte LB; Breedveld FC
    Ned Tijdschr Geneeskd; 2001 Sep; 145(39):1880-5. PubMed ID: 11605312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
    Bombardieri S; Ferraccioli G; Ferri C; Galeazzi M; Lapadula G; Cerinic MM; Montecucco C; Triolo G; Trotta F; Valentini G
    Reumatismo; 2009; 61 Suppl 1():1-23. PubMed ID: 19999184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of etanercept or infliximab treatment on lipid profile and insulin resistance in patients with refractory rheumatoid arthritis.
    Seriolo B; Paolino S; Ferrone C; Cutolo M
    Clin Rheumatol; 2007 Oct; 26(10):1799-800. PubMed ID: 17646897
    [No Abstract]   [Full Text] [Related]  

  • 16. TNF-alpha inhibition: the need for a tumor necrosis factor thermostat.
    O'Dell JR
    Mayo Clin Proc; 2001 Jun; 76(6):573-5. PubMed ID: 11393494
    [No Abstract]   [Full Text] [Related]  

  • 17. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.
    DeWitt EM; Glick HA; Albert DA; Joffe MM; Wolfe F
    Arch Intern Med; 2006 Jan; 166(1):57-63. PubMed ID: 16401811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Symmons DP; Watson KD; Silman AJ;
    Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIO database.
    Ostergaard M; Unkerskov J; Linde L; Krogh NS; Ravn T; Ringsdal VS; Petri A; Andersen LS; Tarp U; Hansen A; Hjardem E; Hetland ML
    Scand J Rheumatol; 2007; 36(2):151-4. PubMed ID: 17476624
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept.
    Fleischmann R; Iqbal I; Nandeshwar P; Quiceno A
    Drug Saf; 2002; 25(3):173-97. PubMed ID: 11945114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.